product name Pomalidomide
273.24
Formula
C13H11N3O4
CAS No.
19171-19-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 55 mg/mL (201.28 mM) )
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: <1 mg/mL
Solubility (In vivo)
1% DMSO+30% polyethylene glycol+1% Tween 80: 15 mg/mL
Chemical Name
4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
other peoduct :
| Pomalidomide at 1 μM increased HbF production in human erythroid cells. After 6 days, Pomalidomide at 1 μM induced γ-globin mRNA levels upregulation 2-fold while decreased β-globin levels 2-fold. | |
|---|---|
| In Vivo | Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. |
| Animal model | Disseminated lymphoma-bearing SCID mice |
| Formulation & Dosage | Dissolved in DMSO to make a 10 mg/mL stock solution and diluted to a final concentration of 1 mg/mL in sterile 0.9% normal saline. 0.5 mg/kg; i.p. |
| References | [1] Hernandez-Ilizaliturri FJ, et al. Clin Cancer Res, 2005, 11(16), 5984-5992. |
